Article

Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study

2022-10-06

Abstract excerpt

<h4>Background: </h4> and Purpose: Despite their use to treat cancers with specific genetic aberrations, targeted therapies elicit heterogeneous responses. Sources of variability are critical to targeted therapy drug development, yet there exists no method to discern their relative contribution to response heterogeneity. Experimental Approach: We use HER2-amplified breast cancer and two agents, neratinib and lapat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b597c3a7-81c9-52ef-bf64-a16ab2ec3b40
DOI: 10.22541/au.166506842.27113533/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case studyDOI 10.22541/au.166506842.27113533/v1Read

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibitionSemantic proximity Read

A unifying framework disentangles genetic, epigenetic, and stochastic sources of drug-response variability in an <i>in vitro</i> model of tumor heterogeneitySemantic proximity Read

Phenotypic deconvolution in heterogeneous cancer cell populations using drug screening dataSemantic proximity Read

An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability.Semantic proximity Read

Spatial Agent-Based Modeling and Interpretable Machine Learning Predict Combination Therapy Response in HER2-Heterogeneous Breast CancerSemantic proximity Read

Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase InhibitorsSemantic proximity Read

THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data.Semantic proximity Read

A drug’s most potent target is not necessarily the source of its anti-cancer activitySemantic proximity Read

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity Read

Identifying the effectiveness of 3D culture systems to recapitulate breast tumor tissue in situ.Semantic proximity Read

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.Semantic proximity Read

Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical ExposuresSemantic proximity Read